KILPEST INDIA LTD. Q1 FY27 Results

3B BlackBio Dx (formerly Kilpest India) reported consolidated Q1 FY27 (quarter ended June 30, 2026) revenue of Rs 33.49 Cr, up 50.62% YoY from Rs 22.23 Cr but down 5.48% QoQ from Rs 35.43 Cr. Consolidated PAT, however, fell to Rs 8.98 Cr, down 28.99% YoY from Rs 12.64 Cr and down 8.43% QoQ from Rs 9.80 Cr; basic EPS was Rs 10.48 versus Rs 14.76 a year ago. The standalone (India-only) entity told a different story: PAT grew 13.25% YoY to Rs 14.11 Cr on revenue of Rs 22.95 Cr (+12.71% YoY) - a divergence well beyond 3%, confirming the group-level profit decline is entirely a consolidation effect from the newly folded-in TRUPCR Europe and Coris Holding (Belgium) subsidiaries, not a slowdown in the core India business.

The margin compression sits squarely on the cost lines added by consolidation: total consolidated expenses rose 147% YoY to Rs 26.41 Cr (versus standalone's +10%), led by employee benefit expenses (+384% YoY to Rs 8.55 Cr) and depreciation/amortisation (+386% YoY to Rs 1.34 Cr). Consolidated net margin (PAT/total income) compressed to 22.65% from 47.62% a year ago, though it improved from 21.51% in the March quarter; operating margin (EBITDA/revenue) fell to 25.45% from 53.22% YoY. Minority interest swung to -Rs 0.55 Cr this quarter from +Rs 0.25 Cr and +Rs 0.06 Cr in the preceding two quarters, indicating the newly consolidated subsidiary base posted a loss attributable to non-controlling shareholders this period.

The stock went into the print at ₹1,220, down 4.6% over the past month of trading.

Management's FY27 guidance (from the Q4 FY26 call) called for 15-20% consolidated revenue growth with "a similar trajectory" for EBITDA, and had flagged Coris BioConcept contributing roughly Rs 50-52 Cr in FY27 revenue with a slight EBITDA-positive impact. Q1 revenue growth of 50.62% YoY clears the top end of that band, but the beat is inorganic (driven by Coris/TRUPCR entering consolidation) rather than core-business acceleration, while EBITDA fell roughly 28% YoY - a clear early miss on the EBITDA leg of guidance. By segment, Diagnostic Kits revenue grew 60.60% YoY to Rs 32.06 Cr but segment PBIT fell 16.32% YoY to Rs 13.32 Cr, since the new subsidiary costs sit inside this segment; Agrochemicals, which the company flags as seasonal and weather-dependent, saw revenue fall 36.95% YoY to Rs 1.43 Cr but was near-breakeven (Rs 0.0003 Cr profit versus a Rs 0.044 Cr loss a year ago). No separate management press release accompanied this filing beyond the board outcome letter, and no independent street/consensus estimates for this print were found in a web search, so the comparison to Street is marked unknown rather than assumed.